芳香化酶抑制剂在乳腺癌新辅助内分泌治疗中的应用

摘要

Neoadjuvant endocrine therapy for breast cancer is a focus issue in recent years. The aro-matase inhibitors are important drugs among it. Newer generation aromatase inhibitors are superior to tamoxifen as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer and have a promising prospect in clinical practice. Still some treatment-related problems remain to be discussed and further researched.%乳腺癌新辅助内分泌治疗是近年来乳腺癌治疗中的新热点,芳香化酶抑制剂是其中的一类重要药物.与三苯氧胺相比,新一代芳香化酶抑制剂用于激素受体阳性的绝经后乳腺癌妇女的新辅助治疗具有明显的优势,临床应用前景广阔,但尚有一些治疗相关的问题值得探讨和进一步研究.